Epilepsy is a disease that disrupts the electrical activity of the nervous system, causing seizures. More than 65 million people in the world have epilepsy. 1 in 26 Americans will develop the disease during their lives. Children are the group most frequently diagnosed with new cases of epilepsy. In the United States, 300,000 children under 14 are affected by the condition. Some may outgrow the disorder, but most will not. The number of senior citizens with epilepsy is also 300,000. People with epilepsy have a range of treatment options, including alternative therapies. The illness is a complex condition, however, and all alternative treatment options must be looked at carefully, to ensure they are effective. Causes of epilepsy Epilepsy is a complex disease that can disrupt the electrical a...
THC comes to mind when a lot of people talk about cannabis, but CBD is getting quite renowned due to its beneficial effects on the body. As scientific research moves step by step forward every day, it becomes clear that every medical cannabis strain has its own properties. CBD helps the brain in an intricate and pertinent manner. There is no psychoactive effect attached to CBD. This makes it different from THC which has some psychoactive effects. This happens because CB1 receptors are not activated by cannabidiol. The manner by which cannabidiol affects the brain shall be explained further.
For the first time, scientists have demonstrated that a component of cannabis reduces seizures in children with a rare form of epilepsy, marking a significant step in efforts to use marijuana and its derivatives to treat serious medical conditions.
A controversial treatment for children with severe epilepsy could become legal nationwide. The treatment uses oil derived from Marijuana. While the treatment is legal in 44 states across the country, the treatment is still a challenge for many to access. Charlotte Figi, 10, is a happy and healthy third-grader from Colorado Springs. It’s a sight, mother, Paige Figi says she thought she’d never witness. Five and a half years ago, she was preparing to say goodbye.
Known as the Therapeutic Hemp Medical Access Act, a bipartisan bill introduced this week seeks to ensure unrestricted access to specific strains high in CBD for individuals battling intractable epilepsy. Requesting an exemption from the Controlled Substance Act (CSA) for “strains of therapeutic hemp” known to be high in Cannabidiol (CBD), the bill was announced and endorsed by nine state senators on Tuesday.
For individuals with a severe form of epilepsy, a new study finds that the occurrence of seizures could be significantly reduced with a daily dose of cannabidiol – a chemical component of cannabis. Researchers say that cannabidiol – an active chemical in cannabis – could help to reduce seizures for patients with Lennox-Gastaut syndrome. Researchers from the Ohio State University found that individuals with Lennox-Gastaut syndrome (LGS) who took cannabidiol every day for 14 weeks saw the frequency of atonic seizures fall by more than 50 percent. Atonic seizures, also known as drop seizures, involve a sudden, brief loss of muscle tone. Study co-author Dr. Anup Patel, of the College of Medicine at Ohio State, and colleagues recently presented their findings at the American A...
Promising results from a large-scale, controlled, Phase 3 clinical study of epilepsy patients being treated with cannabidiol will be presented next week at the American Academy of Neurology’s Annual Meeting in Boston on April 25. GW Pharmaceuticals’ liquid oral formulation of cannabidiol (CBD), called Epidiolex, is one of 500 compounds found in cannabis. Unlike the well-known compound, tetrahydrocannabinol (THC), CBD does not produce a “high” as the psychoactive component is absent. Results from the randomized, double-blind, placebo-controlled study found that almost 40 percent of people with Lennox-Gastaut syndrome (LGS) had at least a 50 percent reduction in drop seizures, compared to 15 percent taking a placebo. LGS is a severe form of epilepsy that often results in impaired intellectua...
We are often judged by the company we keep, even unfairly. For decades, that has been the fate of cannabidiol, a chemical compound that has the bad luck to occur naturally in marijuana, the world’s most controversial plant. Because cannabidiol is subject to the same tight legal restrictions on personal and scientific use as is marijuana, its potential medical benefits have been underappreciated — at least up until now.
A medical cannabis product called RSHO-X dramatically reduced epileptic seizures in a Mexican study of Lennox-Gastaut syndrome, a severe form of childhood epilepsy that responds poorly to treatment. The study covered 39 patients who had daily seizures despite being treated with at least three anti-epileptic drugs. Seventeen percent of the participants had no seizures for at least four months, researchers said. Eighty-four percent had a 50 percent reduction in seizure activity. And more than half, 53 percent, saw their seizure activity drop by 75 percent.
A study finds that people with uncontrolled epilepsy ? neurological disorder ? resort to cannabis products when antiepileptic drug side-effects are intolerable. Epilepsy is a neurological disorder marked by sudden recurrent episodes of sensory disturbance, loss of consciousness, or convulsions, associated with abnormal electrical activity in the brain. University of Sydney researchers revealed that 14 percent of people with epilepsy have used cannabis products as a way to manage seizures.
Intense abnormal activity in well-known brain networks that occurs early in a seizure may be the key to impaired consciousness in children with absence epilepsy, new research suggests.
New open-label data from the expanded-access treatment program involving the cannabidiol Epidiolex (GW Pharma) show the median reduction in frequency of convulsive seizures after 3 months of treatment was 45% in all patients but higher in those with Dravet syndrome, among the most severe types of epilepsy. The data are “very positive and promising,” said lead author Orrin Devinsky, MD, professor, neurology, neurosurgery and psychiatry, and director, New York University Comprehensive Epilepsy Center.